Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?
作者信息
Beevers D G, Sleight P
机构信息
City Hospital, Birmingham.
出版信息
BMJ. 1996 May 4;312(7039):1143-5. doi: 10.1136/bmj.312.7039.1143.
Abstract
摘要
相似文献
1
Short acting dihydropyridine (vasodilating) calcium channel blockers for hypertension: is there a risk?
BMJ. 1996 May 4;312(7039):1143-5. doi: 10.1136/bmj.312.7039.1143.
2
3
Watanidipine. AE 0047, Calbren, GJ 0956, Vatanidipine.瓦尼地平。AE 0047，卡尔布伦，GJ 0956，瓦尼地平。
Drugs R D. 2002;3(5):331-6. doi: 10.2165/00126839-200203050-00007.
4
Effects of long-acting versus short-acting calcium channel blockers among older survivors of acute myocardial infarction.长效与短效钙通道阻滞剂对老年急性心肌梗死幸存者的影响。
J Am Geriatr Soc. 1999 May;47(5):512-7. doi: 10.1111/j.1532-5415.1999.tb02562.x.
5
Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications.1,4-二氢吡啶类钙通道阻滞剂的差异效应：治疗意义
J Clin Pharmacol. 1987 Nov;27(11):825-34. doi: 10.1002/j.1552-4604.1987.tb05576.x.
6
Dihydropyridine calcium channel antagonists in the management of hypertension.二氢吡啶类钙通道拮抗剂在高血压治疗中的应用
Drugs. 2007;67(9):1309-27. doi: 10.2165/00003495-200767090-00005.
7
Use of calcium channel blockers in hypertension.钙通道阻滞剂在高血压治疗中的应用。
Adv Intern Med. 1998;43:533-62.
8
[Evolution of the market of calcium dihydropyridinic antagonists and their use in the treatment of chronic forms of ischemic heart disease].
Lik Sprava. 2002 Jul-Sep(5-6):16-20.
9
Calcium channel blocker debate: true lies?钙通道阻滞剂之争：是真相还是谎言？
Cardiovasc Drugs Ther. 1996 Sep;10(4):413-5. doi: 10.1007/BF00051105.
10
Case studies in hypertension. Dihydropyridine/nondihydropyridine calcium channel blocker combination therapy.高血压病例研究。二氢吡啶类/非二氢吡啶类钙通道阻滞剂联合治疗
J Clin Hypertens (Greenwich). 2005 Jan;7(1):50-3. doi: 10.1111/j.1524-6175.2005.04091.x.
引用本文的文献
1
Amlodipine and valsartan as components of a rational and effective fixed-dose combination.氨氯地平和缬沙坦作为合理有效的固定剂量复方制剂的组成成分。
Vasc Health Risk Manag. 2009;5(1):165-74. doi: 10.2147/vhrm.s3134. Epub 2009 Apr 8.
2
The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension.血管紧张素转换酶抑制剂在高血压治疗中的作用。
Curr Cardiol Rep. 2001 Nov;3(6):511-8. doi: 10.1007/s11886-001-0074-1.
3
Evidence for the risk of calcium channel blockers in hypertension was selective.钙通道阻滞剂治疗高血压存在风险的证据具有选择性。
BMJ. 1996 Nov 16;313(7067):1259-60. doi: 10.1136/bmj.313.7067.1259c.
本文引用的文献
1
Calcium antagonists during and after myocardial infarction.心肌梗死期间及之后使用的钙拮抗剂。
Drugs. 1996 Feb;51(2):216-25. doi: 10.2165/00003495-199651020-00003.
2
Verapamil following uncomplicated myocardial infarction: promising, but not proven.
Am J Cardiol. 1996 Feb 15;77(5):421-2. doi: 10.1016/s0002-9149(97)89376-9.
3
Established populations for epidemiologic studies of the elderly: study design and methodology.老年人流行病学研究的既定人群：研究设计与方法
Aging (Milano). 1993 Feb;5(1):27-37. doi: 10.1007/BF03324123.
4
Surgical bleeding: unexpected effect of a calcium antagonist.
BMJ. 1995 Mar 25;310(6982):776-7. doi: 10.1136/bmj.310.6982.776.
5
Apparatchiks of science share their anxiety.
Lancet. 1995 Sep 9;346(8976):689. doi: 10.1016/s0140-6736(95)92288-1.
6
Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.硝苯地平。冠心病患者死亡率呈剂量相关增加。
Circulation. 1995 Sep 1;92(5):1326-31. doi: 10.1161/01.cir.92.5.1326.
7
8
Long-term survival and use of antihypertensive medications in older persons.老年人长期使用抗高血压药物及其生存情况
J Am Geriatr Soc. 1995 Nov;43(11):1191-7. doi: 10.1111/j.1532-5415.1995.tb07393.x.
9
Nifedipine-associated myocardial ischemia or infarction in the treatment of hypertensive urgencies.硝苯地平在治疗高血压急症时相关的心肌缺血或梗死。
Ann Intern Med. 1987 Aug;107(2):185-6. doi: 10.7326/0003-4819-107-2-185.
10
Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.
Am J Cardiol. 1991 Jun 1;67(15):1295-7. doi: 10.1016/0002-9149(91)90944-g.
Zotero 插件